Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Picks Up Pacific Rim Distributor

NEW YORK (GenomeWeb News) – Genetic Technologies will distribute Rosetta Genomics' cancer diagnostic tests in Australia, New Zealand, and Singapore, under an exclusive agreement announced by Rosetta Genomics today.

GTG, a Melbourne-based genetic testing lab, will market the company's microRNA-based miRview tests in the three countries, Rosetta Genomics said.

The line of tests GTG will offer include the miRview mets, for diagnosing primary tumor site in metastatic cancer patients and patients with cancer of unknown primary origin; the miRview squamous, for differentiating squamous from non-squamous, non-small cell lung cancer; and the miRview meso, for differentiating mesothelioma from other cancers of the lung.

Rosetta Genomics Chief Commercialization Officer Ronen Tamir said in a statement that GTG is the firm's first distributor in the Pacific Rim region.

GTG CEO Paul MacLeman said that his company aims to "leverage in-house developed tests through partnering with third party developers of novel tests," in order to build a portfolio of genetic tests for the oncology market.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.